PRAMEF6

Across TCGA pan-cancer cohorts, PRAMEF6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRAMEF6 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRAMEF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF6 expression acts as an unfavorable survival marker.

LUAD, LUSC, and PRAD are the cancer types where PRAMEF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.163	0.835	<.001	36	view →
LUSC	OS	Median	All	0.138	0.776	<.001	12	view →
PRAD	DFS	Median	All	0.187	0.775	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PRAMEF6–LUAD (OS)

Open the LUAD breakdown →